Filing Details
- Accession Number:
- 0001628280-25-035755
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-07-23 16:35:37
- Reporting Period:
- 2025-07-21
- Filing Date:
- 2025-07-23
- Accepted Time:
- 2025-07-23 16:35:37
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1104506 | Insmed Inc | INSM | Pharmaceutical Preparations (2834) | 541972729 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1604019 | Sara Bonstein | 700 Us Highway 202/206 Bridgewater NJ 08807 | Chief Financial Officer | No | Yes | No | No |
Transaction Summary
Sold: | 58,400 shares | Avg. Price: $102.67 | Total Value: $5,996,093.50 |
Number of Shares After Transactions: | 73,505 shares |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2025-07-21 | 3,443 | $26.46 | 87,460 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2025-07-21 | 11,455 | $28.88 | 98,915 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2025-07-21 | 15,890 | $29.13 | 114,805 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2025-07-21 | 17,100 | $34.03 | 131,905 | No | 4 | M | Direct | |
Common Stock | Disposition | 2025-07-21 | 32,090 | $102.38 | 99,815 | No | 4 | S | Direct | |
Common Stock | Disposition | 2025-07-21 | 26,310 | $103.03 | 73,505 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2025-07-21 | 3,443 | $0.00 | 3,443 | $26.46 |
Common Stock | Stock Option (right to buy) | Disposition | 2025-07-21 | 11,455 | $0.00 | 11,455 | $28.88 |
Common Stock | Stock Option (right to buy) | Disposition | 2025-07-21 | 15,890 | $0.00 | 15,890 | $29.13 |
Common Stock | Stock Option (right to buy) | Disposition | 2025-07-21 | 17,100 | $0.00 | 17,100 | $34.03 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
8,580 | 2031-05-12 | No | 4 | M | Direct | |
0 | 2030-02-03 | No | 4 | M | Direct | |
47,670 | 2034-01-04 | No | 4 | M | Direct | |
0 | 2031-01-07 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 5, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- This is the weighted average sales price representing 32,090 shares sold at prices ranging from $101.77 to $102.76 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- This is the weighted average sales price representing 26,310 shares sold at prices ranging from $102.77 to $103.37 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.
- The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.